A review of 36 studies on GLP-1 medications suggests most of the weight lost comes from fat, not muscle, offering some reassurance to the millions now using these drugs.
GLP-1 medications have moved from niche diabetes treatment to one of the most prescribed drug categories in the country in a remarkably short period. Wegovy, Ozempic, and similar drugs now reach millions of patients, and the clinical conversation around them has shifted from whether they work to what exactly they do to the body over time.
One of the more persistent concerns has been muscle loss. Weight loss drugs have historically tended to reduce lean body mass alongside fat, which raises questions about long-term metabolic health, bone density, and physical function. A new analysis suggests those concerns may be less urgent than the early skepticism implied.
What the research looked at
A study published in the International Journal of Obesity pooled data from 36 previous studies on GLP-1 medications to get a clearer picture of how body composition changes over the course of treatment. The scope matters here. Single studies can be noisy. Thirty-six studies, analyzed together, offer a more stable signal.
After three months on GLP-1 medications, participants showed an average weight loss of around 9%. The majority of that loss came from fat mass, including visceral fat, the kind stored around internal organs that carries the highest metabolic risk. Loss of lean body mass occurred but remained modest relative to the overall reduction in weight.
At the 12-month mark, the pattern held. Fat mass continued to decline substantially while muscle loss stayed limited. That ratio is closer to what clinicians generally consider a favorable body composition outcome than what earlier concerns had suggested.
How doctors are interpreting it
The findings align with what some bariatric physicians say they observe in clinical practice. Dr. Mir Ali, a bariatric surgeon, has described patient outcomes that mirror the study’s results, noting that fat rather than muscle tends to account for the bulk of weight lost on these medications. Dr. Douglas R. Ewing, a medical director focused on weight management, has characterized the quality of weight loss associated with GLP-1 drugs as high, specifically because it skews toward fat reduction.
That framing, quality of weight loss, is worth holding onto. Not all weight loss is equivalent from a health standpoint. Losing predominantly fat while retaining muscle preserves metabolic rate, physical capacity, and long-term body composition in ways that muscle-depleting weight loss does not.
Muscle loss still happens and it can be managed
The research does not suggest muscle loss is zero. It suggests it is lower than feared and lower than what tends to occur with caloric restriction alone, particularly severe restriction. For patients who want to push that number lower still, the evidence on what works is fairly consistent.
Protein intake is the most direct lever. Researchers generally point to a target of 1.0 to 1.2 grams per kilogram of ideal body weight daily, drawn from sources like lean meats, fish, eggs, dairy, tofu, and legumes. That range is higher than most people eating at a caloric deficit naturally hit without tracking.
Resistance training is the other major variable. Lifting weights, using resistance bands, or performing bodyweight movements two to three times a week gives muscles a reason to maintain themselves even as overall caloric intake drops. Aerobic activity adds cardiovascular benefit and supports energy levels, with most guidelines pointing to at least 150 minutes of moderate-intensity movement per week as a reasonable floor.
Sleep is frequently underweighted in weight loss planning. Muscle repair and synthesis happen primarily during sleep, and chronic sleep deprivation undermines both even when protein and training are dialed in.
The broader picture
GLP-1 medications are not a uniform experience. Doses vary, individual responses vary, and the addition or absence of lifestyle changes shapes outcomes considerably. What the 36-study review adds to the conversation is a more evidence-based starting point for patients and clinicians assessing what these drugs actually do to body composition over time.
For anyone currently taking or considering a GLP-1 medication, the muscle question is worth raising directly with a physician or registered dietitian. The answer is increasingly that the risk is real but manageable, and that the tools for managing it are well understood.
